Abstract: This invention relates to a highly reliable material for an organic electroluminescent element exhibiting high luminance, high luminous efficiency, little deterioration in emission, and suitability for use and storage at high temperatures and to an organic electroluminescent element using said material. The material is a diaminodibenzodioxin derivative represented by general formula (1) wherein Ar1, Ar2, Ar3, and Ar4 are substituted or unsubstituted aryl groups and Ar1, Ar2, and the nitrogen atom bonded thereto or Ar3, Ar4, and the nitrogen atom bonded thereto may form a nitrogen-containing heterocyclic ring; and this diaminodibenzodioxin derivative may be incorporated in the light-emitting layer, the hole-transporting layer, or the hole-injecting layer of an organic electroluminescent element.

Abstract: This invention relates to a highly reliable material for an organic electroluminescent element exhibiting high luminance, high luminous efficiency, little deterioration in emission, and suitability for use and storage at high temperatures and to an organic electroluminescent element using said material. The material is a diaminodibenzodioxin derivative represented by general formula (1) wherein Ar1, Ar2, Ar3, and Ar4 are substituted or unsubstituted aryl groups and Ar1, Ar2, and the nitrogen atom bonded thereto or Ar3, Ar4, and the nitrogen atom bonded thereto may form a nitrogen-containing heterocyclic ring; and this diaminodibenzodioxin derivative may be incorporated in the light-emitting layer, the hole-transporting layer, or the hole-injecting layer of an organic electroluminescent element.

Abstract: Methods of using a compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, to treat cancer, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-drug ester has the following generic structure: wherein R1, R2, R3, R4, R5, R6, R7, R8, X1 and X2 are selected from specified residues, as described, and the dashed bond represents either a carbon-carbon single bond or a carbon-carbon double bond.

Abstract: Methods of using a compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, to treat cancer, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-drug ester has the following structure: 1

Abstract: A compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-drug ester has the following structure: wherein: R1, R2, R5, R7,and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, X1 and